Gilead SciencesĀ (NASDAQ:GILD) has had a banner year.

Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations.

CelgeneĀ (NASDAQ:CELG) has had a more mixed experience this year, with concerns about the Revlimid patent and even some less-than-stellar trial data for its up-and-coming drug Otezla.

But Gilead's opportunity is more than just Sovaldi, and Celgene's is more than just Revlimid (and even more than just Revlimid and Otezla).

Are they the best big biotechs?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.

Leaked: This coming blockbuster will make even Gilead and Celgene jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene and Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers